With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more effective? In a press release, Lilly announced that in its latest trial comparing its medication,

New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.